NCT06445907View on ClinicalTrials.gov

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given by IV

DRUG

Venetoclax

Given by PO

DRUG

Q702

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Qurient Co., Ltd.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER